Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label Phase III Trial to Evaluate the Efficacy and Safety of Pertuzumab Retreatment in Previously Pertuzumab, Trastuzuamb and Chemotherapy Treated Her2-Positive Metastatic Advanced Breast Cancer

NCT02514681 is registered in ClinicalTrials.gov with Japan Breast Cancer Research Group as lead sponsor.

NCT NCT02514681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02514681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label Phase III Trial to Evaluate the Efficacy and Safety of Pertuzumab Retreatment in Previously Pertuzumab, Trastuzuamb and Chemotherapy Treated Her2-Positive Metastatic Advanced Breast Cancer
Lead sponsor
Japan Breast Cancer Research Group
Phase
Phase 3
Overall status
Completed
Start date
August 1, 2015
Completion date
August 10, 2022
Enrollment
226 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive locally advanced or metastatic breast cancer